Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22266191 | 0.88 | KDM4E (0.46) | KDM4EHTTPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL1008495 | 0.88 | KDM4E (0.44) | KDM4EHTTPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL1010034 | 0.88 | KDM4E (0.44) | KDM4EHTTPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL12635343 | 0.88 | KDM4E (0.44) | KDM4EHTTPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL22006816 | 0.86 | HTT (0.47) | KDM4EHTTPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL5472061 | 0.82 | KDM4E (0.56) | KDM4EPOLBALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL11010869 | 0.81 | KDM4E (0.50) | KDM4EPOLBALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL1010044 | 0.80 | KDM4E (0.54) | KDM4EPOLBALDH1A1SMN1; SMN2PKM | |
| SCHEMBL1008455 | 0.80 | KDM4E (0.59) | KDM4EPOLBALDH1A1SMN1; SMN2PKM | |
| SCHEMBL1007625 | 0.80 | KDM4E (0.54) | KDM4EHTTPOLBALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633348-B1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARM INC (US) | 2008-10-08 | — | — | EP | claimed |
| US-7432379-B2 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | claimed |
| EP-1633348-A1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Elan Pharmaceuticals, Inc. (US) | 2006-03-15 | — | — | EP | claimed |
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-01-27 | — | — | US | claimed |
| WO-2004098589-A1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | claimed |
| CN-119930602-A | Pyrimidine ring-containing 2, 5-disubstituted thiadiazole compound, and preparation method and application thereof | 山东第二医科大学 | 2025-05-06 | — | — | CN | disclosed |
| CN-115160193-B | Naphthalene sulfonamide micromolecule compound and application thereof | 中国人民解放军海军军医大学 | 2023-09-15 | — | — | CN | disclosed |
| WO-2023083194-A1 | WEE1 PROTEIN KINASE DEGRADATION AGENT AND USE THEREOF | 杭州格博生物医药有限公司 | 2023-05-19 | — | — | WO | disclosed |
| CN-115160193-A | Naphthalene sulfonamide micromolecule compound and application thereof | 中国人民解放军海军军医大学 | 2022-10-11 | — | — | CN | disclosed |
| US-10717720-B2 | Modified compound of andrographolide | HEILONGJIANG ZHENBAODAO PHARMACEUTICAL CO., LTD. (CN) | 2020-07-21 | — | — | US | disclosed |
| EP-2488532-B1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS INC (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-3287463-A1 | CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. (CN) | 2018-02-28 | — | — | EP | disclosed |
| EP-1228070-B1 | HETEROALKYLAMINO-SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE | HOFFMANN LA ROCHE (CH) | 2007-02-07 | — | — | EP | disclosed |
| EP-1633348-A1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Elan Pharmaceuticals, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050261284-A1 | Diazinopyrimidines | CHEN JIAN J | 2005-11-24 | — | — | US | disclosed |
| US-20050215574-A1 | 4-anilino quinazoline derivatives as antiproliferative agents | ASTRAZENECA AB (SE) | 2005-09-29 | — | — | US | disclosed |
| US-6943158-B2 | Diazinopyrimidines | ROCHE PALO ALTO LLC (US) | 2005-09-13 | — | — | US | disclosed |
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-01-27 | — | — | US | disclosed |
| WO-2004098589-A1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| US-20040097493-A1 | For preparing medicaments useful for the therapy of the p38 MAP kinase and FGFR kinase mediated diseases and conditions | HOFFMANN-LA ROCHE INC. | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215574-A1 | 4-anilino quinazoline derivatives as antiproliferative agents | ERBB2, ERBB4, EGFR | KDM4E 1814/4885HTT 3207/4885POLB 1916/4885 |
| US-20050261284-A1 | Diazinopyrimidines | MAPK6, MAPK1, MAP2K6 | KDM4E 4239/4885HTT 2097/4885POLB 3111/4885 |
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | BDKRB1, BDKRB2, BRS3 | KDM4E 4503/4885HTT 3286/4885POLB 2817/4885 |
| US-10717720-B2 | Modified compound of andrographolide | CYP11B2, CYP11B1, DUSP23 | KDM4E 3102/4885HTT 4527/4885POLB 4620/4885 |
| US-20040097493-A1 | For preparing medicaments useful for the therapy of the p38 MAP kinase and FGFR kinase mediated diseases and conditions | FGFR1, MAPK1, FGF1 | KDM4E 4627/4885HTT 2319/4885POLB 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.